Displaying drugs 651 - 675 of 11635 in total
Dutasteride
Dutasteride is an oral synthetic 4-azasteroid commonly marketed under the trade name Avodart. It is a novel dual 5α-reductase inhibitor that works by blocking both isoforms of 5α-reductase enzymes in a potent, selective, and irreversible manner. Type I and II 5α-reductase enzymes convert testosterone into dihydrotestosterone (DHT), a primary hormonal...
Approved
Investigational
Matched Description: … in a potent, selective, and irreversible manner. ... hormonal mediator that plays a role in the development and enlargement of the prostate gland. ... It is a novel dual 5α-reductase inhibitor that works by blocking both isoforms of 5α-reductase enzymes …
Halazepam
Halazepam is a benzodiazepine derivative drug exerting anxiolytic, anticonvulsant, sedative, a muscle relaxing effects.[A1212, A178114] It has been shown to be less toxic than chlordiazepoxide or diazepam. This drug is no longer marketed in the United States, and was withdrawn by Schering, its manufacturer, in 2009.[L6226, L6229]
Approved
Illicit
Withdrawn
Matched Description: … Halazepam is a _benzodiazepine_ derivative drug exerting anxiolytic, anticonvulsant, sedative, a muscle …
Quinethazone
Quinethazone, marketed as Hydromox, is a thiazide diuretic indicated for hypertension. Patients may experience adverse reactions such as dizziness, dry mouth, nausea, and hypokalemia.
Approved
Matched Description: … Quinethazone, marketed as Hydromox, is a thiazide diuretic indicated for hypertension. …
Sarecycline
Sarecycline is a semi-synthetic derivative of tetracycline that was initially discovered by Paratek Pharmaceuticals from Boston, MA but then licensed to Warner Chilcott of Rockaway, NJ in July of 2007 . After completing various phase-II and phase-III trials demonstrating its effectiveness in treating moderate to severe facial acne vulgaris [A39993,...
Approved
Investigational
Matched Description: … s Seysara (sarecylcine) as a new first in class narrow spectrum tetracycline derived oral antibiotic ... Sarecycline is a semi-synthetic derivative of tetracycline that was initially discovered by Paratek Pharmaceuticals ... Medical Dermatology portfolio, before Almirall acquired the portfolio in the second half of 2018 as a …
Tafamidis
Tafamidis and tafamidis meglumine (FX-1006A) are benzoxazole derivatives developed by FoldRX. Tafamidis is structurally similar to diflusinal. Tafamidis was granted an EMA market authorisation on 16 November 2011 and FDA approval on 3 May 2019.
Approved
Investigational
Cisatracurium
Cisatracurium is a non-depolarising neuromuscular blocking agent of the benzylisoquinolinium class, available in its salt form, cisatracurium besylate.[A243416,A253592] Cisatracurium has an intermediate duration of action and is one of the most commonly used neuromuscular blocking agents in intensive care.[A253592,A253597]. Cisatracurium acts on cholinergic receptors, blocking neuromuscular transmission. This action is...
Approved
Investigational
Matched Description: … [A243416] Compared to atracurium, cisatracurium produces a lower degree of histamine release. ... Cisatracurium is a non-depolarising neuromuscular blocking agent of the benzylisoquinolinium class, available …
Interferon alfa-n1
Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated. This differs from recombinant alpha interferons, which are individual non-glycosylated proteins produced from individual alpha interferon genes.
Approved
Investigational
Taliglucerase alfa
Taliglucerase alfa is the recombinant active form of the human lysosomal enzyme, β-glucocerebrosidase. It was approved in 2012 and is marketed under the name Elelyso for use in patients with type 1 Gaucher's disease.
Approved
Investigational
Ammonium carbonate
Approved
Experimental
Omadacycline
Omadacycline has been used in trials studying the treatment of Bacterial Pneumonia, Bacterial Infections, Community-Acquired Infections, and Skin Structures and Soft Tissue Infections. Omadacycline represents a significant advance over the well-known tetracycline family, and has been shown to be highly effective in animal models at treating increasingly problematic, clinically prevalent...
Approved
Investigational
Matched Description: … Omadacycline represents a significant advance over the well-known tetracycline family, and has been shown …
Hexocyclium
Hexocyclium is a muscarinic acetylcholine receptor antagonist which was presumably used in the treatment of gastric ulcer or diarrhea. It was once available under the tradename Tral marketed by Abbvie Inc. but has been discontinued. Proton pump inhibitors like DB00338 and opiate anti-diarrheal agents like DB00836 have largely replaced the...
Approved
Matched Description: … Hexocyclium is a muscarinic acetylcholine receptor antagonist which was presumably used in the treatment …
Glucagon
Glucagon is a 29 amino acid hormone used as a diagnostic aid in radiologic exams to temporarily inhibit the movement of the gastrointestinal tract and to treat severe hypoglycemia.[L7634,L7637,L7640,L7643,L8519] Glucagon raises blood sugar through activation of hepatic glucagon receptors, stimulating glycogenolysis and the release of glucose.[L7640,L7643]
Glucagon was granted FDA...
Approved
Matched Description: … Glucagon is a 29 amino acid hormone used as a diagnostic aid in radiologic exams to temporarily inhibit …
Scorpion (centruroides) immune Fab2 antivenin (equine)
Centruroides (scorpion) Immune F(ab')2 (equine) is a purified preparation of immune globulin F(ab’)2 fragments that are derived from plasma of the horses immunized with venom of C. noxius, C. l. limpidus, C. l. tecomanus, and C. s. suffusus. It is intravenously administered patients with clinical signs of scorpion envenomation so...
Approved
Matched Description: … This drug is a polyvalent antivenin proven to be useful against scorpion stings. ... Centruroides (scorpion) Immune F(ab')2 (equine) is a purified preparation of immune globulin F(ab’)2 ... Envenomation by a scorpion sting can result in serious cardiovascular effects [A32483]. …
Rufinamide
Rufinamide is a triazole derivative and an anticonvulsant medication to treat seizure disorders like Lennox-Gastuat syndrome, a form of childhood epilepsy. Clinical trials suggest its efficacy in the treatment of partial seizures.
Approved
Matched Description: … Lennox-Gastuat syndrome, a form of childhood epilepsy. ... Rufinamide is a triazole derivative and an anticonvulsant medication to treat seizure disorders like …
Oteracil
Oteracil is an adjunct to antineoplastic therapy, used to reduce the toxic side effects associated with chemotherapy. Approved by the European Medicines Agency (EMA) in March 2011, Oteracil is available in combination with DB09257 and DB09256 within the commercially available product "Teysuno". The main active ingredient in Teysuno is DB09256,...
Approved
Matched Description: … The main active ingredient in Teysuno is [DB09256], a pro-drug of [DB00544] (5-FU), which is a cytotoxic ... By mimicking a class of compounds called "pyrimidines" that are essential components of RNA and DNA, …
Glutethimide
Glutethimide is a hypnotic and sedative. Its use has been largely superseded by other drugs.
Approved
Illicit
Matched Description: … Glutethimide is a hypnotic and sedative. Its use has been largely superseded by other drugs. …
Ketorolac
Ketorolac is a Non-steroidal anti-inflammatory drug (NSAID) and is commercially available as an oral tablet, injectable, nasal spray and as an ophthalmic solution. It's analgesic properties make it a useful pain management tool across many settings including postoperative pain, rheumatoid arthritis, osteoarthritis, menstrual disorders, headaches, spinal and soft tissue pain,...
Approved
Matched Description: … it a useful opioid sparing agent. ... Ketorolac is a Non-steroidal anti-inflammatory drug (NSAID) and is commercially available as an oral ... [L6358][L6508][L11055][L3674][L11070]
It's analgesic properties make it a useful pain management …
Lorazepam
Lorazepam is a short-acting and rapidly cleared benzodiazepine used commonly as a sedative and anxiolytic. It was developed by DJ Richards, presented and marketed initially by Wyeth Pharmaceuticals in the USA in 1977. The first historic FDA label approval is reported in 1985 by the company Mutual Pharm.
Approved
Matched Description: … Lorazepam is a short-acting and rapidly cleared benzodiazepine used commonly as a sedative and anxiolytic …
Formoterol
Formoterol is an inhaled beta2-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers....
Approved
Investigational
Matched Description: … [L10986] It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic ... [A189528] A major clinical advantage of formoterol over other inhaled beta-agonists is its rapid onset ... of action (2-3 minutes), which is at least as fast as [salbutamol], combined with a long duration of …
Vinorelbine
Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC) . It was initially approved in the USA in 1990's for the treatment of NSCLC .
It is a third-generation vinca alkaloid. The introduction...
Approved
Investigational
Matched Description: … It is a third-generation vinca alkaloid. ... was found that there was 4.3-fold variation in vinorelbine clearance across the cohort, suggesting a ... A study was done on the clearance rate of vinorelbine on individuals with various single polymorphonuclear …
Matched Categories: … Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index …
Matched Categories: … Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index …
Efalizumab
Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. The FDA approved efalizumab in 2003. It was later withdrawn...
Approved
Investigational
Withdrawn
Matched Description: … Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ... ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. ... It was later withdrawn in 2009 due to a potential risk of progressive multifocal leukoencephalopathy …
Lidoflazine
Approved
Experimental
Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen
Haemophilus influenzae type b strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen is an active immunization as a booster dose given intramuscularly to pediatric patients who have received a primary series with a Haemophilus b Conjugate Vaccine that is licensed for primarly immunization. The vaccine contains Haemophilus b capsular polysaccharide...
Approved
Investigational
Matched Description: … booster dose given intramuscularly to pediatric patients who have received a primary series with a Haemophilus ... strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen is an active immunization as a ... vaccine contains Haemophilus b capsular polysaccharide (polyribosyl-ribitol-phosphate [PRP]), which is a …
SARS-CoV-2 virus recombinant spike (S) protein receptor binding domain (RBD) fusion heterodimer (B.1.351-B.1.1.7 strains)
Bimervax is an adjuvanted non-mRNA COVID-19 vaccine utilizing a SARS-CoV-2 recombinant spike (S) protein receptor binding domain (RBD) fusion heterodimer. It is intended to elicit protection against Omicron XBB.1.5, one of the dominant circulating SARS-CoV-2 subvariants in 2023. It is produced using recombinant DNA technology in CHO cell lines and...
Approved
Matched Description: … Bimervax is an adjuvanted non-mRNA COVID-19 vaccine utilizing a SARS-CoV-2 recombinant spike (S) protein ... [L48902,L48907]
Bimervax was issued marketing authorization in the EU in March 2023 for use as a booster …
Displaying drugs 651 - 675 of 11635 in total